Clinical Trial Update: Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 [Phase 2]

View source ↗

Summary

A Phase IIb clinical study evaluating the recombinant Mycobacterium tuberculosis allergen ESAT6-CFP10 for tuberculosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• ESAT6-CFP10 (recombinant Mycobacterium tuberculosis allergen ESAT6-CFP10)

Snippet

Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Conditions: Tuberculosis | Phase 2 | Status: COMPLETED